Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety
Autore:
Peuskens, J; De Hert, M; Jones, M;
Indirizzi:
Univ Centrum St Jozef, Kortenberg, Belgium Univ Centrum St Jozef Kortenberg Belgium St Jozef, Kortenberg, Belgium Macquarie Univ, Dept Psychol, Sydney, NSW, Australia Macquarie Univ Sydney NSW Australia Dept Psychol, Sydney, NSW, Australia
Titolo Testata:
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
fascicolo: 3, volume: 5, anno: 2001,
pagine: 179 - 187
SICI:
1365-1501(200109)5:3<179:TCVORA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-SCHIZOPHRENIC PATIENTS; DOUBLE-BLIND; PSYCHOTIC DISORDERS; ACUTE EXACERBATIONS; PARALLEL-GROUP; HALOPERIDOL; TRIAL; PLACEBO; MULTICENTER; SYMPTOMS;
Keywords:
novel antipsychotics; conventional neuroleptics; schizophrenia; meta-analysis; risperidone; olanzapine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Jones, M POB 55, Mt Kuring Gai, NSW 2080, Australia POB 55 Mt Kuring Gai NSW Australia 2080 Gai, NSW 2080, Australia
Citazione:
J. Peuskens et al., "The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety", INT J PSYC, 5(3), 2001, pp. 179-187

Abstract

Introduction: Since 1990 novel antipsychotics have been available to treatschizophrenia. Risperidone and olanzapine have emerged as the two most popular members of this class. The current report aims to synthesize the clinical trial data currently available on these two novel antipsychotics and compare them with conventional products in terms of efficacy and safety. Methods: Published randomized clinical trials, which included a risperidone or olanzapine arm, were sought through the MEDLINE, EMBASE and PSYCLIT databases. Trials were only excluded due to reporting failures or design incompatibilities (not randomized). A random effects approach was applied to compare information across trials, and meta-regression was used to compare product categories and gain insight into patient factors related to clinical outcomes. Outcome variables measured were total Positive and Negative Symptom Scale (PANSS) score, withdrawals due to inefficacy and use of medicationfor extrapyramidal symptoms (EPS). Results: Risperidone and olanzapine offer advantages over conventional products in terms of both efficacy and safety. Of the two novel antipsychoticsstudied, the benefits of risperidone were clearer than those with olanzapine in terms of efficacy; this could not be assessed for safety due to inconsistencies in the reporting of extrapyramidal symptoms between studies. Conclusion: Patients receiving, novel antipsychotics, particularly risperidone, are likely to gain improved control of symptoms of schizophrenia and are less likely to require medication to counteract extrapyramidal symptomsthan patients receiving conventional neuroleptics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/12/19 alle ore 12:11:15